Cold Urticaria: Ice Cube Testing, Critical Temperature Threshold & Anaphylaxis Risk

Clinical Overview

Cold-induced urticaria (CIU) is a physical urticaria triggered by exposure to cold temperatures, occurring in 0.05-3% of the general population. It manifests as pruritic wheals and angioedema that develop during or shortly after contact with cold stimuli (air, water, ice) and resolve within 30 minutes of rewarming. This distinguishes CIU from chronic spontaneous urticaria, where lesions persist for prolonged periods. Cold urticaria can be acquired or familial (rare) and is classified into two main types: primary acquired CIU and secondary CIU (associated with cryoglobulinemia, cold agglutinins, or other underlying conditions).

Epidemiology & Risk Factors

Acquired CIU accounts for 90% of cases and typically presents in late childhood, adolescence, or early adulthood. Females are affected more frequently than males. Risk factors and associations include:

• Idiopathic: No identifiable underlying disease in 90% of primary acquired CIU
• Underlying systemic disease: Cryoglobulinemia, cold agglutinin disease, systemic lupus erythematosus, hepatitis C, lymphoproliferative disorders (associated with secondary CIU in 10%)
• Familial cold autoinflammatory syndrome (FCAS): Rare autosomal dominant disorder caused by NLRP3 inflammasome mutations, presenting with fever, arthritis, and cold-triggered rash

Natural history: Approximately 50% of primary acquired CIU patients remit spontaneously within 5 years; others have chronic disease lasting decades.

Pathophysiology

The exact mechanism of CIU is not fully understood. Current understanding involves:

• Mast cell activation: Cold exposure triggers mast cell degranulation and histamine release, likely through direct cold-sensing mechanisms or via complement activation
• Complement pathway: Cold-induced complement activation (particularly C3a and C5a generation) may contribute to mast cell activation and increased vascular permeability
• Cryoproteins: In secondary CIU, cryoglobulins or cold agglutinins precipitate in cold temperatures, triggering immune activation and complement cascade
• Cold-sensing transient receptor potential (TRP) channels: TRPM8 and TRPA1 on nerve fibers and possibly immune cells respond to cold and may trigger neuropeptide release (CGRP, substance P) that contributes to vascular responses

The release of histamine, tryptase, IL-6, TNF-α, and other mediators increases vascular permeability and produces wheals and angioedema.

Clinical Presentation & Classification

Acquired CIU: Pruritic wheals develop during or immediately after cold exposure (air temperature, swimming, cold water immersion, ice contact). Lesions typically appear on exposed areas (face, hands) or areas in contact with cold surfaces (buttocks during swimming). Wheals resolve rapidly (within 30 minutes) upon rewarming. Angioedema may develop, particularly affecting lips and throat.

Severity classification (Critical Temperature Threshold): The minimum temperature that triggers urticaria within 5 minutes of exposure. Patients with lower thresholds have more severe disease (triggered by minimal cold exposure).

Systemic symptoms: Severe cases may present with systemic symptoms including syncope, bronchospasm, or anaphylaxis upon rapid rewarming or full-body cold exposure (e.g., cold water immersion). Patients with severe CIU should avoid unmonitored swimming or rapid rewarming.

Secondary CIU: Associated with constitutional symptoms (fever, malaise, arthralgias) suggesting underlying systemic disease.

Diagnosis & Workup

Clinical diagnosis: Based on history of characteristic symptoms triggered by cold exposure and confirmed by cold challenge test.

Ice cube test: Place ice cube directly on skin (typically on forearm) for 5 minutes or until threshold response occurs. Positive test: wheal development at or within 5 minutes of ice contact. This is the standard diagnostic test in clinical practice.

Differential diagnosis and workup:

• Other physical urticarias: Dermographism (stroking skin produces wheals), pressure urticaria (prolonged pressure), exercise-induced urticaria, solar urticaria, aquagenic urticaria (water contact)
• Screening for secondary CIU:
• Complete blood count (cytopenias, atypical lymphocytes)
• Comprehensive metabolic panel (renal/liver disease)
• Cryoglobulins level and cold agglutinins
• Hepatitis C antibody (HCV associated with cryoglobulinemia)
• ANA and complement levels (SLE screening)
• LDH and lymphocyte count (lymphoproliferative disease screening)
• Serum protein electrophoresis if abnormal CBC or symptoms of systemic disease

Severity assessment: Critical temperature threshold testing (ice cube at different temperatures or standardized cold challenge) determines minimum temperature triggering urticaria and guides counseling.

Treatment Algorithm

Step 1: Avoidance and Patient Education

First-line management is cold avoidance. Patients should:

• Avoid prolonged cold exposure and unmonitored swimming
• Wear protective clothing (gloves, winter jackets) in cold weather
• Avoid rapid rewarming after cold exposure (which can trigger rebound urticaria)
• Gradual rewarming to body temperature is safer than hot water immersion
• Consider carrying epinephrine auto-injector (EpiPen) if anaphylaxis risk is present
• Inform family members and caregivers of the diagnosis and symptoms

Many patients with mild CIU require only avoidance and need no pharmacotherapy.

Step 2: Antihistamines

Second-generation H1-antihistamines (first-line pharmacotherapy):

• Cetirizine 10 mg daily
• Desloratadine 5 mg daily
• Fexofenadine 180 mg daily

Take antihistamine 30 minutes to 1 hour before anticipated cold exposure for maximum effect. Approximately 50-60% of CIU patients achieve adequate control with antihistamines. If inadequate response, escalate to high-dose antihistamines (up to 4-fold standard dose).

Step 3: Advanced Pharmacotherapy

Cyclosporine: 1-5 mg/kg/day (divided doses) for antihistamine-refractory CIU. Response rates 60-80% in small case series. Requires monitoring renal function and blood pressure.

Omalizumab: 150-375 mg SC monthly. Emerging evidence suggests benefit in some CIU patients, though data are more limited than for chronic spontaneous urticaria. Consider trial in severe refractory cases.

JAK inhibitors: Baricitinib and other JAK inhibitors show promise in preclinical and early clinical studies; not yet standard of care but may be considered for refractory disease.

Prognosis & Complications

Approximately 50% of primary acquired CIU remits spontaneously within 5 years. Others have chronic disease lasting decades. The major complications are systemic reactions (anaphylaxis, syncope, bronchospasm) upon cold water immersion or rapid rewarming—rare but potentially fatal. Secondary CIU associated with cryoglobulinemia or other systemic disease has a prognosis dependent on the underlying condition.

When to See a Dermatologist

Referral to dermatology is indicated for:

• Diagnosis confirmation via ice cube test or cold challenge
• Assessment of disease severity and critical temperature threshold
• Symptoms suggesting secondary CIU or systemic disease
• Inadequate response to antihistamines
• Counseling on avoidance, life modifications, and emergency preparedness

Frequently Asked Questions

Is cold urticaria dangerous? Can it be life-threatening?

In most cases, cold urticaria causes uncomfortable itching and swelling but is not dangerous. However, severe cold urticaria can be life-threatening in specific situations. The main risk occurs with rapid full-body cold exposure, such as swimming in cold water or accidental immersion. In severe cases, this can trigger anaphylaxis (a severe allergic reaction) with symptoms including low blood pressure, loss of consciousness, or difficulty breathing. For this reason, patients with severe cold urticaria should avoid swimming without supervision and should carry an epinephrine auto-injector. Most cases of cold urticaria are mild to moderate and managed with avoidance and antihistamines, carrying minimal risk.

Why do my symptoms get worse when I warm up?

Rebound urticaria (worsening during rewarming) is a common and puzzling feature of cold urticaria. During cold exposure, blood vessels constrict and histamine release is limited. When the skin is rapidly rewarmed (such as by immersing a cold hand in hot water), blood vessels dilate rapidly and additional mast cell degranulation occurs, triggering more histamine release and urticaria. This is why gradual rewarming to body temperature is safer than immersing cold skin in hot water. Wrap cold skin in warm (not hot) blankets or use body heat for gradual rewarming.

Does cold urticaria mean I have an underlying disease?

In most cases (90%), acquired cold urticaria is primary and not associated with underlying systemic disease. However, in 10% of cases, cold urticaria is secondary to another condition such as cryoglobulinemia (an autoimmune disorder), hepatitis C, systemic lupus erythematosus (SLE), or lymphoproliferative disorders. If you develop cold urticaria, your physician will perform screening blood tests (including tests for cryoglobulins, cold agglutinins, hepatitis C antibody, and autoimmune markers) to exclude these secondary causes. If screening is normal, you likely have primary cold urticaria without underlying systemic disease.

Will my cold urticaria go away, and how long will it last?

Approximately 50% of patients with primary acquired cold urticaria experience spontaneous remission within 5 years. Others have persistent disease lasting 10-20 years or longer. Unfortunately, there is no way to predict at diagnosis whether your cold urticaria will remit spontaneously or persist. The natural course is highly variable. The good news is that avoidance and antihistamines effectively control symptoms in most patients, allowing them to maintain quality of life despite the condition. Modern therapies (cyclosporine, omalizumab) are available for those with refractory disease.

References